Cipla Share Price

Cipla Limited is a pharmaceutical company founded in 1935 by Khwaja Abdul Hamied. Headquartered in Mumbai, Cipla is one of the most popular pharma brands in India. It ranks as the third-largest pharmaceutical company in India and third within the private pharmaceutical market in South Africa.

The market capitalisation of Cipla Limited is over ₹1,03,000 crore as of January 5, 2024. Cipla share price has gained over 55% in three years.

Business operations

Cipla specialises in developing diverse formulations across various sectors in the pharmaceutical industry.

The company's products include drugs for Alzheimer's, arthritis, Parkinson's and cardiovascular diseases.

In recent times, Cipla has introduced several innovative products. This includes the I-Pill, an oral emergency contraceptive. It also introduced No Touch Breast Scan (NTBS) technology – and advanced, painless, non-invasive and radiation-free method for early breast cancer detection in India.

Moreover, they have launched generic versions of anti-flu medications like oseltamivir and zanamivir locally, targeting H1N1 influenza treatment.

Cipla has a wide reach to more than 85 countries, offering over 1,500 products covering diverse in over 50 different dosage forms. Its 2001 initiative of introducing a triple antiretroviral therapy for HIV/AIDS at less than a dollar a day in Africa is widely recognised for its significant contribution to promoting "inclusivity, accessibility and affordability" within the HIV movement.

Cipla mainly operates under the following three segments-

Generics and Branded Generics:

Cipla's Generics division in India accounts for 19% of its pharmaceutical revenues, collaborating with over 4,000 partners. Despite operating in a competitive market that comprises over 5,000 pharmaceutical players, Cipla has emerged as one of the biggest players in this segment.

Speciality:

In the past two years, Cipla has directed its efforts towards its Engine 2.0 of growth, centred on innovation and speciality medicine. The company has allocated huge capital to acquire products that cater to the unmet clinical needs of patients.

The primary aim of this division has been to develop a portfolio of specialty medicines in respiratory and critical care. Realising the significant operational differences between a speciality-focused company and a generic one, Cipla Technologies LLC (CipTec) has been established in San Diego, California.

Consumer Health:

Nicotex, Cipla's leading smoking-quitting brand, holds the top position in its category. ActivKids ImmunoBoosters, a chocolate-form nutritional supplement for kids, marked Cipla's debut in outlets in this segment. It also collaborated with Kidzania, a kids’ edutainment hub in Mumbai and Delhi to establish a permanent presence for generating trials.

The brand engaged in school contact programmes, reaching out to 700,000 kids for sampling and exposure.

Cofsils cough drops, introduced as part of a brand extension strategy, facilitated Cipla Health's entry into the herbal throat lozenge market.

Financial Highlights

Cipla Limited's revenue from operations for FY23 stood at ₹22,753 crore, up 4.6% from ₹21,763 crore in FY22. The company recorded a profit (profit after tax) of ₹2,833 crore in FY23 against ₹2,547 crore in FY22. In FY23, the earnings before interest, taxes, depreciation and amortisation (EBITDA) increased to ₹5,027 crore from the previous year's ₹4,578 crore. The company's earnings per share (EPS) stood at ₹34.72 in FY23 compared to ₹31.2 in the previous financial year.